• search

Natco Pharma launches Bortezomib injection

Written by: Staff

New Delhi, Aug 24 (UNI) Natco Pharma Ltd today announced the launch of its brand Bortenat (Bortezomib) 3.5 mg injection, used in the treatment of multiple myeloma, a type of blood cancer.

Bortenat is the first time launch of the Bortezomib generic in the world, in addition to being a first time introduction in India for the company.

''Natco Pharma expects Bortenat to catapult the company to the number one position among the domestic companies in the oncology segment,'' a company statement said.

Consistent with its policy of making life saving drugs affordable, the company has priced Bortenat at Rs 16,800 as against Rs 75,000 of the imported medicine.

This is the company's most significant launch after Imatinib Mesylate (launched under the brand name VEENAT).

Being a pre-1995 invention, the company does not expect any litigation around this molecule.

Multiple Myeloma (characterised by the abnormal plasma cell in the bone marrow) is cancer of the plasma cell, which represents the immune system that produces immunoglobulins to help fight infection and disease.

From among the several types of blood cancers, Multiple Myeloma is the second most prevalent and represents one percent of all cancers.

Multiple Myeloma attributes about 2 per of all the cancer deaths.

In majority of the cases found, multiple myeloma appears to have affected people over 40 years.


For Daily Alerts

For Breaking News from Oneindia
Get instant news updates throughout the day.

Notification Settings X
Time Settings
Clear Notification X
Do you want to clear all the notifications from your inbox?
Settings X
We use cookies to ensure that we give you the best experience on our website. This includes cookies from third party social media websites and ad networks. Such third party cookies may track your use on Oneindia sites for better rendering. Our partners use cookies to ensure we show you advertising that is relevant to you. If you continue without changing your settings, we'll assume that you are happy to receive all cookies on Oneindia website. However, you can change your cookie settings at any time. Learn more